Leaflet: information for the patient
Vitelax 50 mg film-coated tablets EFG
Vitelax 100 mg film-coated tablets EFG
Vitelax 150 mg film-coated tablets EFG
Vitelax 200 mg film-coated tablets EFG
lacosamide
Read the entire leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the leaflet
5 Conservation of Vitelax
What is Vitelax
Vitelax contains lacosamide, which belongs to a group of medications called "antiepileptic medications". These medications are used to treat epilepsy.
What Vitelax is used for
Do not take Vitelax
Do not take lacosamide if any of the above applies to you. If you are not sure, consult your doctor or pharmacist before taking this medication.
Warnings and precautions
Consult your doctor before starting to take lacosamide:
If any of the above applies to you (or you are not sure), consult your doctor or pharmacist before taking lacosamide.
If you are taking lacosamide, consult your doctor if you experience a new type of seizure or worsening of existing seizures.
If you are taking lacosamide and experience symptoms of abnormal heartbeat (such as slow, fast, or irregular heartbeat, palpitations, shortness of breath, dizziness, fainting), consult your doctor immediately (see section 4).
Children
Lacosamide is not recommended in children under 2 years of age with epilepsy characterized by the onset of partial seizures or in children under 4 years of age with primary generalized tonic-clonic seizures. This is because it is not yet known if it is effective and safe for children in this age group.
Other medications and Vitelax
Tell your doctor or pharmacist if you are taking, have recently taken, or may need to take any other medication.
In particular, tell your doctor or pharmacist if you are taking any of the following medications that affect the heart, as this medication may also affect the heart:
If any of the above applies to you (or you are not sure), talk to your doctor or pharmacist before taking lacosamide.
Also, inform your doctor or pharmacist if you are taking any of the following medications, as they may also increase or decrease the effect of this medication in your body:
If any of the above applies to you (or you are not sure), talk to your doctor or pharmacist before taking this medication.
Taking Vitelax with alcohol
As a precaution, do not take lacosamide with alcohol.
Pregnancy and breastfeeding
Women of childbearing age should discuss the use of contraceptives with their doctor.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Lacosamide is not recommended if you are pregnant, as its effects on pregnancy and the fetus are not known.
It is not recommended to breastfeed while taking lacosamide, as lacosamide passes into breast milk.
Seek immediate advice from your doctor if you are pregnant or plan to become pregnant. They will help you decide whether to take this medication or not.
Do not stop treatment without talking to your doctor first, as this may increase the risk of seizures (crises). Worsening of your condition may also harm the fetus.
Driving and using machines
Do not drive, ride a bike, or use any tools or machines until you know if this medication affects you. The reason is that lacosamide can cause dizziness or blurred vision.
Follow the administration instructions for this medication exactly as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again. Other presentations of lacosamide may be more suitable for children; consult your doctor or pharmacist.
Taking Vitelax
Normally, you will start by taking a low dose every day, and your doctor will gradually increase the dose over several weeks. When you reach the dose that works well for you, called the "maintenance dose", you will take the same amount every day. This medication is used as long-term treatment. You will need to continue taking lacosamide until your doctor tells you to stop.
How much to take
The following are the usual recommended doses of lacosamide for different age and weight groups. Your doctor may prescribe a different dose if you have kidney or liver problems.
Adolescents and children weighing 50 kg or more and adults:
When taking Vitelax alone:
The usual starting dose is 50 mg twice a day.
Your doctor may also prescribe a starting dose of 100 mg of lacosamide twice a day.
Your doctor may increase the dose you take twice a day by 50 mg each week, until you reach a maintenance dose between 100 mg and 300 mg twice a day.
When taking Vitelax with other antiepileptic medications:
The usual starting dose is 50 mg twice a day.
Your doctor may increase the dose you take twice a day by 50 mg each week, until you reach a maintenance dose between 100 mg and 200 mg twice a day.
If you weigh 50 kg or more, your doctor may start lacosamide treatment with a single "loading dose" of 200 mg. Then, you will start taking the continuous maintenance dose 12 hours later.
Children and adolescents weighing less than 50 kg:
The dose depends on body weight. Treatment is usually started with the syrup and only changed to tablets if the patient is able to take them and get the correct dose with tablets of different concentrations. Your doctor will prescribe the pharmaceutical form that best suits you.
If you take more Vitelax than you should
If you have taken more lacosamide than you should, consult your doctor immediately. Do not attempt to drive. You may experience:
In case of overdose or accidental ingestion, consult your doctor or call the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
If you forget to take Vitelax
If you stop taking Vitelax
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not everyone experiences them.
Side effects on the nervous system, such as dizziness, may be greater after a single "loading dose".
Tell your doctor or pharmacist if you experience any of the following effects:
Very common:may affect more than 1 in 10 patients
Common:may affect up to 1 in 10 patients
Uncommon:may affect up to 1 in 100 patients
Frequency not known:cannot be estimated from available data
Blood tests may show a severe decrease in a specific class of white blood cells (agranulocytosis);
Other side effects in children
Additional side effects observed in children were fever (pyrexia), runny nose (nasopharyngitis), sore throat (pharyngitis), decreased appetite, behavioral changes, not acting as they normally do (abnormal behavior), and lack of energy (lethargy). Drowsiness (somnolence) is a very common side effect in children and may affect more than 1 in 10 children.
Reporting side effects
If you experience any side effects, consult your doctor or pharmacist, even if they are side effects not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medications: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date shown on the box and on the blister after CAD. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Medications should not be disposed of through wastewater or household waste. Deposit the packaging and medications you no longer need at the SIGRE collection point in your pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. This will help protect the environment.
Vitelax Composition
Each 50 mg Vitelax tablet contains 50 mg of lacosamide.
Each 100 mg Vitelax tablet contains 100 mg of lacosamide.
Each 150 mg Vitelax tablet contains 150 mg of lacosamide.
Each 200 mg Vitelax tablet contains 200 mg of lacosamide.
Tablet Core:microcrystalline cellulose, crospovidone, hydroxypropylcellulose, anhydrous colloidal silica, and magnesium stearate.
Coating Material:
50 mg: white coating agent, composed of: hypromellose, titanium dioxide (E171), macrogol, and talc.
100 mg: yellow coating agent, composed of: hypromellose, titanium dioxide (E171), macrogol, talc, yellow iron oxide (E172), and red iron oxide (E172).
150 mg: beige coating agent, composed of: hypromellose, titanium dioxide (E171), macrogol, talc, yellow iron oxide (E172), red iron oxide (E172), and black iron oxide (E172).
200 mg: blue coating agent, composed of: hypromellose, titanium dioxide (E171), macrogol, talc, indigo carmine (E132), red iron oxide (E172), and brilliant blue FCF (E133).
Product Appearance and Container Content
Vitelax 50 mg are film-coated oval tablets, white or off-white in color, with beveled edges, marked with “787” on one side and smooth on the other, with dimensions of 10 mm x 5 mm.
The tablets are presented in blisters packaged in boxes of 14 tablets.
Vitelax 100 mg are film-coated oval tablets, yellow or yellowish in color, with beveled edges, marked with “788” on one side and smooth on the other, with dimensions of 13 mm x 6 mm.
The tablets are presented in blisters packaged in boxes of 56 tablets.
Vitelax 150 mg are film-coated oval tablets, beige in color, with beveled edges, marked with “789” on one side and smooth on the other, with dimensions of 14 mm x 7 mm.
The tablets are presented in blisters packaged in boxes of 56 tablets.
Vitelax 200 mg are film-coated oval tablets, light blue or blue in color, with beveled edges, marked with “790” on one side and smooth on the other, with dimensions of 16.2 mm x 7.9 mm.
The tablets are presented in blisters packaged in boxes of 56 tablets.
Marketing Authorization Holder
Laboratorios Combix, S.L.U.
C/ Badajoz 2, Edificio 2
28223 Pozuelo de Alarcón (Madrid)
Spain
Manufacturer
Zydus France
ZAC Les Hautes Patures
Parc d'activités des Peupliers
25 Rue des Peupliers
92000 Nanterre
France
or
Centre Spécialités Pharmaceutiques
ZAC des Suzots
35 rue de la Chapelle
63450 Saint Amant Tallende
France
or
Netpharmalab Consulting Services S.L.
Carretera de Fuencarral 22
28108 Alcobendas, Madrid
Spain
or
Flavine Pharma France
3 Voie d’Allemagne
13127 Vitrolles,
France
Date of Last Revision of this Prospectus: December 2024
Detailed information about this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/)